Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Merck
Chinese Patent Office
Julphar
Accenture
Deloitte
AstraZeneca
Argus Health
Citi
Cantor Fitzgerald

Generated: January 18, 2018

DrugPatentWatch Database Preview

Indivior Inc Company Profile

« Back to Dashboard

What is the competitive landscape for INDIVIOR INC, and what generic alternatives to INDIVIOR INC drugs are available?

INDIVIOR INC has four approved drugs.

There are four US patents protecting INDIVIOR INC drugs.

There are one hundred and thirty patent family members on INDIVIOR INC drugs in twenty-five countries.

Summary for Indivior Inc
International Patents:130
US Patents:4
Tradenames:3
Ingredients:2
NDAs:4

Drugs and US Patents for Indivior Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-004 Aug 10, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 020733-002 Oct 8, 2002 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-004 Aug 10, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-001 Aug 30, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 020733-001 Oct 8, 2002 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Indivior Inc SUBUTEX buprenorphine hydrochloride TABLET;SUBLINGUAL 020732-002 Oct 8, 2002 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Indivior Inc BUPRENEX buprenorphine hydrochloride INJECTABLE;INJECTION 018401-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-001 Aug 30, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-001 Aug 30, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-004 Aug 10, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for INDIVIOR INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sulingual Film 12 mg/3 mg ➤ Subscribe 3/26/2014
➤ Subscribe Sublingual Film 4 mg/1 mg ➤ Subscribe 5/14/2013
➤ Subscribe Sublingual Film 2 mg/0.5 mg and 8 mg/2 mg ➤ Subscribe 10/15/2012

Non-Orange Book US Patents for Indivior Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,824,588 Method of making self-supporting therapeutic active-containing film ➤ Subscribe
8,685,437 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom ➤ Subscribe
2,016,206,639 ➤ Subscribe
7,910,641 PH modulated films for delivery of actives ➤ Subscribe
8,906,277 Process for manufacturing a resulting pharmaceutical film ➤ Subscribe
8,900,498 Process for manufacturing a resulting multi-layer pharmaceutical film ➤ Subscribe
8,765,167 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions ➤ Subscribe
8,900,497 Process for making a film having a substantially uniform distribution of components ➤ Subscribe
9,108,340 Process for manufacturing a resulting multi-layer pharmaceutical film ➤ Subscribe
7,357,891 Process for making an ingestible film ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Indivior Inc Drugs

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cipla
Farmers Insurance
Queensland Health
Argus Health
US Department of Justice
Moodys
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot